Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma

Cancer

Volumn 106, Issue 7, 2006, Pages 1548-1553

  Mai, Hai Qiang ^a   Zeng, Zong Yuan ^a   Zhang, Chang Qing ^a   Feng, Kai Tao ^a   Guo, Xiang ^a   Mo, Hao Yuan ^a   Deng, Man Quan ^a   Min, Hua Qing ^a   Hong, Ming Huang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Big endothelin 1; Distant metastases; Nasopharyngeal carcinoma; Prognosis

Indexed keywords

ENDOTHELIN 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; TREATMENT FAILURE;

ADULT; CARCINOMA; CASE-CONTROL STUDIES; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33645818167     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21790     Document Type: Article

References (28)

1. Cassisi NJ. Tumors of the pharynx. In: Thawley SE, Panje WR, Batsakis JG, Lindberg RD, editors. Comprehensive Management of Head and Neck Tumors. Philadelphia: W.B. Saunders, 1987:614-683.
2. Min HQ. Nasopharyngeal carcinoma. In: Gun GY, editor. Epidemiology. Beijing: People's Medical Press, 1996:280-285.
3. Altun M, Fandi A, Dupuis O, Cvitkovic E, Krajina Z, Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys. 1995;32:859-877.
4. Langendijk JA, Leemans ChR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004;22:4604-4612.
5. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989;86:2863-2867.
6. Kusuhara M, Yamaguchi K, Nagasaki K, et al. Production of endothelin in human cancer cell lines. Cancer Res. 1990;50:3257-3261.
7. Shichiri M, Hirata Y, Nakajima T, et al. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest. 1991;87:1867-1871.
8. Bagnato A, Catt KJ. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab. 1998;9:378-383.
9. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer. 2003;88:163-166.
10. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110-116.
11. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA. 2003;100:10954-10959.
12. Elahi MM, Everson NW. Prognosis of colorectal cancer patients with elevated endothelin-1 concentrations. Asian J Surg. 2004;27:4-9.
13. Arun C, DeCatris M, Hemingway DM, London NJ, O'Byrne KJ. Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. Int J Biol Markers. 2004;19:262-267.
14. Hemsen A, Ahlborg G, Ottosson-Seeberger A, Lundberg JM. Metabolism of big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept. 1995;55:287-297.
15. Fleming ID, Cooper JS, Henson DE (eds.). American Joint Committee on Cancer manual for staging of cancer, 5th ed. Philadelphia: Lippincott-Raven, 1997.
16. Shanmugaratnam K, Sobin LH. Histological typing of tumors of the upper respiratory tract and ear. In: World Health Organization International Histological Classification of Tumors, 2nd ed. Berlin: Springer, 1991:32-33.
17. Ma J, Mai HQ, Hong MH, et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys. 2001;50:1181-1189.
18. Al-Sarraf M, LeBlanc M, Shanker Giri PG, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal carcinoma: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310-1317.
19. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631-637.
20. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97:536-539.
21. Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol. 2004;22:2643-2653.
22. Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC. Another way to estimate outcome of advanced nasopharyngeal carcinoma-is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys. 2004;60:156-164.
23. Ferrari-Bravo A, Franciosi C, Lissoni P, Fumagalli L, Uggeri F. Effects of oncological surgery on endothelin-1 secretion in patients with operable gastric cancer. Int J Biol Markers. 2000;15:56-57.
24. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, MO) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys. 1996;35:463-469.
25. Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1350-1357.
26. Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer. 1998;83:2270-2283.
27. Teo PM, Chan AT, Lee WY, Leung TW, Johnson PJ. Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. Int J Radiat Oncol Biol Phys. 1999;43:261-271.
28. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005;23:1118-1124.